William Blair reaffirmed their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a report published on Friday, AnalystRatings.com reports. William Blair also issued estimates for Dynavax Technologies’ Q2 2019 earnings at ($0.64) EPS, Q3 2019 earnings at ($0.52) EPS, Q4 2019 earnings at ($0.37) EPS, FY2019 earnings at ($2.16) EPS, Q1 2020 earnings at ($0.36) EPS, Q2 2020 earnings at ($0.32) EPS, Q3 2020 earnings at ($0.31) EPS, Q4 2020 earnings at ($0.28) EPS and FY2020 earnings at ($1.28) EPS.
Several other research firms have also recently weighed in on DVAX. Cantor Fitzgerald restated an overweight rating and set a $28.00 price target (down from $32.00) on shares of Dynavax Technologies in a report on Tuesday, February 26th. BidaskClub lowered shares of Dynavax Technologies from a sell rating to a strong sell rating in a research report on Thursday, May 30th. Zacks Investment Research lowered shares of Dynavax Technologies from a hold rating to a sell rating in a research report on Thursday, March 14th. Finally, ValuEngine lowered shares of Dynavax Technologies from a hold rating to a sell rating in a research report on Wednesday, May 1st. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus price target of $23.67.
Dynavax Technologies stock opened at $3.80 on Friday. Dynavax Technologies has a fifty-two week low of $3.57 and a fifty-two week high of $16.35. The stock has a market capitalization of $254.40 million, a PE ratio of -1.49 and a beta of 0.89. The stock’s 50-day moving average price is $5.30. The company has a current ratio of 5.27, a quick ratio of 4.61 and a debt-to-equity ratio of 4.88.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. The business had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $5.95 million. During the same period in the previous year, the company earned ($0.63) earnings per share. The firm’s revenue for the quarter was up 3294.1% compared to the same quarter last year. On average, equities analysts predict that Dynavax Technologies will post -2.13 EPS for the current fiscal year.
In other Dynavax Technologies news, SVP Robert Coffman sold 32,218 shares of Dynavax Technologies stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $4.58, for a total value of $147,558.44. Following the sale, the senior vice president now owns 132,470 shares of the company’s stock, valued at $606,712.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.90% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of DVAX. Advisor Group Inc. raised its position in shares of Dynavax Technologies by 515.3% in the fourth quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 3,746 shares during the period. Quantamental Technologies LLC bought a new stake in shares of Dynavax Technologies in the first quarter valued at approximately $62,000. BNP Paribas Arbitrage SA raised its position in shares of Dynavax Technologies by 56,326.1% in the first quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 12,955 shares during the period. Pearl River Capital LLC bought a new stake in shares of Dynavax Technologies in the first quarter valued at approximately $106,000. Finally, Legal & General Group Plc raised its position in shares of Dynavax Technologies by 18.7% in the fourth quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,860 shares during the period. 81.94% of the stock is currently owned by institutional investors.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Further Reading: Stochastic Momentum Index (SMI)
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.